{"id":109514,"date":"2026-06-08T12:10:06","date_gmt":"2026-06-08T06:40:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=109514"},"modified":"2026-06-08T12:10:07","modified_gmt":"2026-06-08T06:40:07","slug":"nifty-pharma-rises-fourth-day-sun-pharma-alkem-labs-june-8-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nifty-pharma-rises-fourth-day-sun-pharma-alkem-labs-june-8-2026\/","title":{"rendered":"Nifty Pharma Rises 0.40% for Fourth Straight Day on June 8, 2026 as Sun Pharma and Alkem Labs Gain Despite Broad Market Crash"},"content":{"rendered":"
<\/div>\n

Nifty Pharma 24,343.90 (+0.40%) June 8 2026. 4th straight gain. Sun Pharma Rs 1,797.90 (+0.88%). Alkem Rs 5,377.50 (+2.40%). Dr Reddy’s Rs 1,287.20 (+0.70%). 52W High 25,043.<\/em><\/p>\n

Nifty Pharma<\/a> extended its winning streak to four consecutive sessions on June 8, 2026, rising 0.40% to 24,343.90, even as the broader market fell and most sectoral indices closed in the red. Sun Pharma led the index with a 0.88% gain to Rs 1,797.90, followed by Alkem Laboratories with a strong 2.40% rise to Rs 5,377.50 and Dr Reddy’s Laboratories up 0.70% to Rs 1,287.20. The Nifty Pharma index has now outperformed virtually every other sectoral index across its four-day run.<\/p>\n

The pharmaceutical sector’s resilience in today’s session, where multiple other indices fell 1-2% on crude oil and rate hike concerns, illustrates its structural defensive characteristics. Pharma demand is largely inelastic to geopolitical shocks, crude oil price spikes, and interest rate cycles, making it a preferred safe haven when macro headwinds intensify across cyclical sectors.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Stock<\/th>\nSymbol<\/th>\nCMP<\/th>\nChange (%)<\/th>\nOpen<\/th>\nHigh<\/th>\n<\/tr>\n<\/thead>\n
Sun Pharma<\/a><\/td>\nSUNPHARMA<\/td>\nRs 1,797.90<\/td>\n+0.88%<\/td>\nRs 1,780.70<\/td>\nRs 1,803.50<\/td>\n<\/tr>\n
Alkem Laboratories<\/a><\/td>\nALKEM<\/td>\nRs 5,377.50<\/td>\n+2.40%<\/td>\nRs 5,250.00<\/td>\nRs 5,399.00<\/td>\n<\/tr>\n
Dr Reddy’s<\/a><\/td>\nDRREDDY<\/td>\nRs 1,287.20<\/td>\n+0.70%<\/td>\nRs 1,270.00<\/td>\nRs 1,293.70<\/td>\n<\/tr>\n
Cipla<\/a><\/td>\nCIPLA<\/td>\nRs 1,392.80<\/td>\n-0.61%<\/td>\nRs 1,397.00<\/td>\nRs 1,405.00<\/td>\n<\/tr>\n
Divi’s Laboratories<\/a><\/td>\nDIVISLAB<\/td>\nRs 6,610.50<\/td>\n-0.19%<\/td>\nRs 6,571.00<\/td>\nRs 6,710.00<\/td>\n<\/tr>\n
Nifty Pharma Index<\/td>\nIndex<\/td>\n24,343.90<\/td>\n+0.40%<\/td>\nN\/A<\/td>\nN\/A<\/td>\n<\/tr>\n
Nifty Healthcare Index<\/td>\nIndex<\/td>\n15,536.95<\/td>\n+0.83%<\/td>\nN\/A<\/td>\nN\/A<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

3 Stocks Building Serious Momentum Right Now<\/p>\n

When Univest analysts<\/strong> identify high-conviction stock opportunities, investors pay attention.<\/em><\/p>\n

Our research team has shortlisted the Top Stocks to Buy<\/strong> based on current market momentum, sector trends & growth potential for 2026.<\/p>\n